Superluminal Medicines Raises $60 Million to Advance Obesity Drug Program
Superluminal Medicines has closed a $60 million Series B financing round. The funds will support the advancement of its lead program targeting rare genetic forms of obesity into clinical trials.
Biotechnology firm Superluminal Medicines announced it has secured $60 million in a Series B financing round, led by BVF Partners, L.P. The round also saw participation from Deep Track Capital and Perceptive Advisors, along with existing investors.
Proceeds from the financing will be allocated to advancing the company's lead drug program into clinical studies. This program focuses on rare genetic conditions contributing to obesity, aiming to provide new therapeutic options for patients with limited treatment alternatives.
Superluminal Medicines specializes in the development of treatments for metabolic disorders, with a specific emphasis on rare genetic causes of obesity. The company leverages advanced understanding in genetics and molecular biology to design targeted therapies.
The capital injection will also bolster the expansion of Superluminal Medicines' research and development capabilities and support team growth. The company has previously received investment from a range of notable venture capital firms and pharmaceutical partners.